Evidence map›Paper›PMID 35948960›Full record

ArticleBMC health services research2022

Risk factors for development of personal protective equipment induced headache: e-survey of medical staff in Baltic states.

Mantas Jokubaitis, Reda Timofejavaitė, Mark Braschinsky, Linda Zvaune, Alo-Rainer Leheste, Laura Gribuste, Paula Mattila, Sintija Strautmane, Austėja Dapkutė, Kristina Ryliškienė

Open access · goldAbstract read
In one paragraph

Article in BMC health services research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Mantas JokubaitisCentre of Neurology, Vilnius University, Vilnius, Lithuania. mantas.jokubaitis1@gmail.com.
Reda TimofejavaitėCentre of Neurology, Vilnius University, Vilnius, Lithuania.
Mark BraschinskyNeurology Clinic, Tartu University Hospital, Tartu, Estonia.
Linda ZvauneDepartment of Neurology and Neurosurgery, Riga East Clinical University Hospital, Riga, Latvia.
Alo-Rainer LehesteNeurology Clinic, Tartu University Hospital, Tartu, Estonia.
Laura GribusteDepartment of Neurology, Pauls Stradins Clinical University Hospital, Riga, Latvia.
Paula MattilaFaculty of Medicine, University of Tartu, Tartu, Estonia.
Sintija StrautmaneDepartment of Neurology, Pauls Stradins Clinical University Hospital, Riga, Latvia.
Austėja DapkutėCentre of Neurology, Vilnius University, Vilnius, Lithuania.
Kristina RyliškienėCentre of Neurology, Vilnius University, Vilnius, Lithuania.
Vilnius University · LTUniversity of Tartu · EEPauls Stradiņš Clinical University Hospital · LVRiga East University Hospital · LVRiga Stradiņš University · LVTartu University Hospital · EE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic led to an unprecedented increase in the use of personal protective equipment (PPE) among medical personnel. The goal of this study was to determine the risk factors and frequency of PPE-induced headache during the COVID-19 pandemic.

methodsFrom January 25 to March 1, 2021, an anonymous online survey was undertaken in the Baltic states.

resultsIn total, 2132 individuals participated. 52.3% experienced a PPE-induced headache. Usual onset time was between 2-3 h, lasting up to 1 h after PPE removal. The most common localization was in temporal and frontal regions. Headache usually occurred 2 to 3 days per week with an average pain score of 5.04 ± 1.80 points. Higher risk was associated with discomfort/pressure OR = 11.55, heat stress OR = 2.228, skin conditions OR = 1.784, long PPE use (duration 10-12 h) OR = 2,18, headache history prior PPE use OR = 1.207. Out of 52.3% respondents with PPE-induced headache, 45.5% developed de novo headache, whereas 54.5% had headache history. Statistically significant differences of PPE-induced headache between respective groups included severity (4.73 vs 5.29), duration (≥ 6 h 6.7% vs 8.2%), accompanying symptoms (nausea (19.3% vs 25.7%), photophobia (19.1% vs 25.7%), phonophobia (15.8% vs 23.5%), osmophobia (5.3% vs 12.0%)) and painkiller use (43.0% vs 61.7%).

conclusionsOver half of the medical personnel reported headache while using PPE. The risk was higher in individuals with headache history, increased duration of PPE use and discomfort while using PPE. Predisposed individuals reported PPE-induced headache which persisted longer, was more intense and debilitating than in the respondents with de novo headache.

Indexed as

COVID-19Personal Protective EquipmentHeadacheHealth PersonnelHumansMedical StaffPandemicsRisk FactorsSurveys and QuestionnairesHeadacheMedical personnelPersonal protective equipment

Identifiers

PMID35948960
PMCPMC9363870
OpenAlexW4291396356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.